“…Planning for new clinical trials combined with informatics approaches to assess biomedical imaging technologies . Enhancement of cooperation among NIH, FDA, HCFA, and industry (both large and small businesses) to improve the speed with which new imaging technologies, probes, and contrast agents can be transferred into clinical practice such as nanoparticles (liposomes or emulsions) [Lanza et al, 1992[Lanza et al, , 1996a[Lanza et al, , 1996bSipkins et al, 1998], dendrimers [Wiener et al, 1994;Bryant et al, 1999], viral constructs [Bulte et al, 2001a], or various polymers [Ma et al, 2001;Roessler et al, 2001] can be loaded with large payloads ( Fig. 1) of imaging agents such as paramagnetic or supraparamagnetic metals, fluorophores, or radionuclides to enable detection with standard imaging equipment.…”